Meanwhile, Trump has already slapped a new 15 per cent global tariff on all imports, via section 122, and may try to invoke ...

In our preoccupation with words, we have lost sight of the tough realities that cannot be softened simply by flattering people’s self-image.” This was not the first book in which Lasch had wondered ...

That boom is already turning to bust. Manufacturing jobs have fallen under Trump, who promised to bring industrial work back ...

This week in the Swamp, I’m lucky to have as my correspondent Matt Duss, the executive vice-president at the Center for International Policy, and a foreign policy adviser to progressives like Senator ...

The Biden administration tried but couldn’t quite get there. Here, I come back to Bad Bunny. His set design included mock sugar cane fields, a reference to the long history of slavery in the Caribbean ...

The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when ...

Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials. In 2025, Moderna spent $3.1 billion on ...

Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine and recent, high-profile pushback from the Food ...

An experimental medicine from BridgeBio Pharma, the San Francisco-area biotechnology company, has succeeded in a late-stage clinical trial as a treatment for the most common type of dwarfism, results ...

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.

The letter amounts to another new regulatory hurdle in the U.S. for Moderna, whose mRNA technology helped end the COVID-19 pandemic but has since become a target of federal health officials under the ...

The Food and Drug Administration rejected a gene therapy Regenxbio has been developing for a rare disease called Hunter syndrome, in a decision that marks the latest blow for a field that has seen ...